Icr - Institut De Chirurgie Réparatrice Locomoteur Et Sports

Icr - Institut De Chirurgie Réparatrice Locomoteur Et Sports company information, Employees & Contact Information

Updated May 2026

Quick answer

Icr - Institut De Chirurgie Réparatrice Locomoteur Et Sports is a Hospitals and Health Care company and founded in 2020. It has approximately 21 employees on record. Contact data was last refreshed in May 2026. Find Icr - Institut De Chirurgie Réparatrice Locomoteur Et Sports's verified employee emails, phone numbers, headquarters address, and key decision makers below.

Notre équipe est composée de chirurgiens orthopédiques de renommée internationale, experts dans le traitement des blessures sportives et des maladies dégénératives des articulations comme l’arthrose. Ils ont reçu le plus haut niveau de formation et participent à leur tour à partager leurs connaissances et les résultats de leurs travaux de recherche pour former les médecins de demain.
Looking for a particular Icr - Institut De Chirurgie Réparatrice Locomoteur Et Sports employee's phone or email?

Icr - Institut De Chirurgie Réparatrice Locomoteur Et Sports Questions

News

ICR welcomes NICE recommendation of capivasertib for advanced breast cancer - The Institute of Cancer Research

ICR welcomes NICE recommendation of capivasertib for advanced breast cancer The Institute of Cancer Research

ICR Accepted NICE’s Recommendation for Olaparib in Advanced Breast Cancer - Oncodaily

ICR Accepted NICE’s Recommendation for Olaparib in Advanced Breast Cancer Oncodaily

ICR welcomes NICE recommendation of olaparib for advanced breast cancer - The Institute of Cancer Research

ICR welcomes NICE recommendation of olaparib for advanced breast cancer The Institute of Cancer Research

ICR responds to NICE decision on olaparib for women with advanced ovarian cancer - The Institute of Cancer Research

ICR responds to NICE decision on olaparib for women with advanced ovarian cancer The Institute of Cancer Research

ICR responds to NICE approval of new breakthrough drugs on the NHS for women with advanced breast cancer - The Institute of Cancer Research

ICR responds to NICE approval of new breakthrough drugs on the NHS for women with advanced breast cancer The Institute of Cancer Research

The ICR responds to NICE’s recommendation not to approve abiraterone as first-line treatment for advanced prostate cancer - The Institute of Cancer Research

The ICR responds to NICE’s recommendation not to approve abiraterone as first-line treatment for advanced prostate cancer The Institute of Cancer Research

Statement about NICE decision on T-VEC for treating inoperable metastatic melanoma - The Institute of Cancer Research

Statement about NICE decision on T-VEC for treating inoperable metastatic melanoma The Institute of Cancer Research

ICR welcomes NICE’s decision to reassess abiraterone as first-line treatment for advanced prostate cancer - The Institute of Cancer Research

ICR welcomes NICE’s decision to reassess abiraterone as first-line treatment for advanced prostate cancer The Institute of Cancer Research

The ICR responds to decision by NICE not to recommend abiraterone as first-line treatment for advanced prostate cancer - The Institute of Cancer Research

The ICR responds to decision by NICE not to recommend abiraterone as first-line treatment for advanced prostate cancer The Institute of Cancer Research

ICR responds to NICE decision about CAR T immunotherapy for non-Hodgkin lymphoma - The Institute of Cancer Research

ICR responds to NICE decision about CAR T immunotherapy for non-Hodgkin lymphoma The Institute of Cancer Research

ICR responds to NICE approval of palbociclib for treating advanced breast cancer after hormone therapy - The Institute of Cancer Research

ICR responds to NICE approval of palbociclib for treating advanced breast cancer after hormone therapy The Institute of Cancer Research

The ICR responds to decision by NICE not to recommend pembrolizumab as first-line treatment for advanced head and neck cancer - The Institute of Cancer Research

The ICR responds to decision by NICE not to recommend pembrolizumab as first-line treatment for advanced head and neck cancer The Institute of Cancer Research

Top Icr - Institut De Chirurgie Réparatrice Locomoteur Et Sports Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant